/PRNewswire/ Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced.
PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer, pancreatic
NEW YORK CITY (dpa-AFX) - Envisagenics announced a research collaboration agreement with Bristol Myers Squibb (BMY). The collaboration will leverage Envisagenics' SpliceCore AI platform to identify